Skip to main content
. 2022 Dec 2;11(12):2395. doi: 10.3390/antiox11122395

Figure 7.

Figure 7

Roles of the PVN in the effects of intravenous infusion (iv) of DEX on the LPS-induced sympathetic activation. Intravenous infusion of DEX for 4 h was carried out 24 h after intraperitoneal injection (ip) of LPS. Bilateral PVN microinjection was performed 5 min before the infusion of DEX. (A) Effects of DEX (2 or 8 ng/Kg/min, iv) on the LPS-induced RSNA, MAP and HR changes (* p < 0.05 vs. Saline+Saline) († p < 0.05 vs. LPS+Saline) (‡ p < 0.05 vs. LPS+DEX) (2 ng/Kg/min); (B,C) effects of DEX (2 or 8 ng/Kg/min, iv) on the LPS-induced heart rate variability changes and plasma norepinephrine level changes; (D) effects of PVN microinjection of yohimbine (10 nmol) or DETC (10 nmol) on the roles of DEX (8 ng/Kg/min, iv) in inhibiting LPS-induced RSNA, MAP and HR changes; (E,F) effects of intravenous infusion (iv) of DEX on the roles of the LPS-induced changes in oxidative stress and inflammation in the PVN; (G,H) effects of microinjection of yohimbine (10 nmol) or DETC (10 nmol) in the PVN on the roles of DEX in inhibiting LPS-induced changes in oxidative stress and inflammation in the PVN (* p < 0.05. n = 6).